Special Issue Title:

Molecular Pathological Approach to Uterine Mesenchymal Tumors and Malignant Tumors for the Establishment of New Diagnostic and Therapeutic Methods

Deadline for manuscript submissions: 31 October 2023

Print Special Issue Flyer (7)

Special Issue Editor

  • Guest Editor

    Prof. Takuma HayashiE-MailWebsite

    National Hospital Organization Kyoto Medical Center, Japan

    Interests: Leiomyoma; Leiomyosarcoma; Ovarian Cancer

Special Issue Information

Dear Colleagues,

Uterine mesenchymal tumours, including uterine leiomyosarcoma (uLMS), are gynaecologic tumours difficult to treat clinically. To our knowledge, no standard clinical treatment for uLMS has been established in any clinical practice guideline. The primary reason for the lack of established treatment is the difficulty of conducting clinical trials because of the low incidence of uterine sarcoma. In many patients, uterine sarcoma develops within the body of the uterus. The development of sarcomas outside the body of the uterus (i.e. vagina, vulva, ovaries, etc.) is rare. A clinical study of uterine sarcoma revealed that the incidence of uterine sarcoma was 8% of malignancies that developed in the body of the uterus. Uterine sarcoma is classified into carcinosarcoma, a mixed epithelial and mesenchymal tumour, and mesenchymal tumor (uLMS, endometrial stromal sarcoma, adenosarcoma, etc.). Approximately 50% of all uterine sarcomas are carcinosarcomas, and most of the other 50% are uLMSs, adenosarcomas and endometrial stromal sarcomas (ESS). Based on the results of clinical studies so far, uterine sarcomas are roughly classified into three. In clinical practice, cancer sarcoma (46%), leiomyosarcoma (36%) and ESS (13%) are found in descending order of frequency of uterine sarcoma. The peak age of onset is approximately 50 years for uLMS and ESS, whereas that for carcinosarcoma is ≥60 years. The 50% survival for ESS is approximately 76 months, whereas that for carcinosarcoma or uLMS is approximately 27 and 30 months, respectively. Due to the low incidence of uterine sarcoma and the subtle differences in the same histology, the molecular pathological diagnosis of uterine sarcoma is often difficult in clinical practice. The clinical treatment strategy and prognosis of uterine sarcoma are determined based on the molecular pathological diagnosis of the resected uterine sarcoma tissue. Therefore, gynaecologists, radiologists and pathologists need to share molecular pathological information to determine the clinical, surgical and pathological diagnosis of uterine sarcoma.

Prof. Takuma Hayashi

Guest Editor


Leiomyoma; Leiomyosarcoma; Ovarian cancer; Cervical cancer; Endometrial cancer

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (1 papers)

Molecular pathological approach to uterine mesenchymal tumors and malignant tumors for the establishment of new diagnostic and therapeutic methods

Takuma Hayashi

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time